Genscript Biotech Corporation (1548.HK)

HKD 10.62

(1.92%)

Total Liabilities Summary of Genscript Biotech Corporation

Genscript Biotech Corporation's latest annual total liabilities in 2023 was 1.34 Billion USD , up 13.45% from previous year.
Genscript Biotech Corporation's latest quarterly total liabilities in 2024 Q2 was 1.5 Billion USD , up 12.26% from previous quarter.
Genscript Biotech Corporation reported annual total liabilities of 1.18 Billion USD in 2022, up 39.89% from previous year.
Genscript Biotech Corporation reported annual total liabilities of 846.17 Million USD in 2021, up 33.93% from previous year.
Genscript Biotech Corporation reported quarterly total liabilities of 1.34 Billion USD for 2023 FY, up 13.45% from previous quarter.
Genscript Biotech Corporation reported quarterly total liabilities of 1.34 Billion USD for 2023 Q4, up 3.44% from previous quarter.

Annual Total Liabilities Chart of Genscript Biotech Corporation (2023 - 2013)

Historical Annual Total Liabilities of Genscript Biotech Corporation (2023 - 2013)

Year	Total Liabilities	Total Liabilities Growth
2023	1.34 Billion USD	13.45%
2022	1.18 Billion USD	39.89%
2021	846.17 Million USD	33.93%
2020	631.81 Million USD	22.18%
2019	517.11 Million USD	22.05%
2018	423.67 Million USD	53.54%
2017	275.94 Million USD	556.84%
2016	42.01 Million USD	27.98%
2015	32.82 Million USD	7.16%
2014	30.63 Million USD	2.5%
2013	29.88 Million USD	0.0%

Year	Total Liabilities	Total Liabilities Growth
2024 Q2	1.5 Billion USD	12.26%
2023 FY	1.34 Billion USD	13.45%
2023 Q4	1.34 Billion USD	3.44%
2023 Q2	1.29 Billion USD	9.68%
2022 FY	1.18 Billion USD	39.89%
2022 Q4	1.18 Billion USD	-5.75%
2022 Q2	1.25 Billion USD	48.42%
2021 Q4	846.17 Million USD	16.12%
2021 FY	846.17 Million USD	33.93%
2021 Q2	728.71 Million USD	15.34%
2020 Q2	554.35 Million USD	7.2%
2020 Q4	631.81 Million USD	13.97%
2020 FY	631.81 Million USD	22.18%
2019 FY	517.11 Million USD	22.05%
2019 Q2	422.95 Million USD	-0.17%
2019 Q4	517.11 Million USD	22.26%
2018 Q4	423.67 Million USD	7.74%
2018 FY	423.67 Million USD	53.54%
2018 Q2	393.22 Million USD	42.5%
2017 Q4	275.94 Million USD	563.33%
2017 FY	275.94 Million USD	556.84%
2017 Q2	41.6 Million USD	-0.98%
2016 FY	42.01 Million USD	27.98%
2016 Q4	42.01 Million USD	11.3%
2016 Q2	37.74 Million USD	14.99%
2015 FY	32.82 Million USD	7.16%
2015 Q2	23.73 Million USD	-18.67%
2015 Q4	32.82 Million USD	38.28%
2014 FY	30.63 Million USD	2.5%
2014 Q4	29.18 Million USD	0.0%
2013 FY	29.88 Million USD	0.0%

Peer Total Liabilities Comparison of Genscript Biotech Corporation

Name	Total Liabilities	Total Liabilities Difference
Uni-Bio Science Group Limited	152.81 Million HKD	-778.789%
CK Life Sciences Int'l., (Holdings) Inc.	7.05 Billion HKD	80.973%